BioReliance Updates Big Blue Mouse Assay Service
BioReliance updates Big Blue Mouse Assay service to meet OECD test requirements.
SPOTLIGHT EVENT
IVT’s 19th AnnualValidation Week
RELATED ARTICLES
BioReliance
, SAFC’s biologics and early-development services business, has qualified the Big Blue Mouse Transgenic Rodent Mutation (TRM) assay to meet the new Organization for Economic Co-Operation and Development (OECD) Test Guideline 488 requirements for evaluation of
in vivo
mutagenicity.
Big Blue is identified in OECD Test Guideline 488 and recommended by the European Chemicals Agency as an accepted assay for evaluating mutagenicity in somatic and male germ cell tissues.
BioReliance acquired the exclusive ownership of the Big Blue TRM assay and rodents from Agilent in March 2013.
Source: BioReliance
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Intertek to Expand UK GMP Facility with 6000 Square Feet of Lab and Office Space
May 7th 2025The company said the expansion is in response to globally rising demand for inhaled biologics, which offer distinct advantages in route of administration, but can be challenging products for developers.
